Key highlights
- Confirmed overall response rate of 68% observed at the 240 mg dose level
- Median progression-free survival reached 16.0 months for the 240 mg cohort
- Intracranial activity demonstrated by a 47% confirmed response rate in brain metastases
- Complete molecular response achieved by 80% of evaluable patients by the third treatment cycle
- Safety profile remained manageable and consistent with previous clinical study observations
Clinical Trial Outcomes
ArriVent BioPharma publicized peer-reviewed results from its FURTHER Phase 1b trial (FURMO-002) in the medical journal Cancer Cell. The study evaluated firmonertinib, an oral EGFR inhibitor, in patients with advanced non-small cell lung cancer (NSCLC) harboring PACC mutations. Data indicated a confirmed overall response rate of 68% and a median progression-free survival of 16.0 months at the 240 mg dose. These findings emphasize the potential for firmonertinib as a targeted, chemotherapy-free treatment for a subset of lung cancer that accounts for approximately 12% of EGFR-mutant tumors, a population currently lacking an established targeted standard of care.
Pipeline and Strategic Significance
- Provides clinical validation for the ongoing global Phase 3 ALPACCA trial (FURMO-006)
- Demonstrates enhanced in vitro potency compared to current treatments like osimertinib for PACC mutations
- Confirms high brain penetrability with meaningful intracranial activity in 41% of patients with baseline metastases
- Establishes ctDNA clearance as a viable molecular correlate for positive clinical outcomes
- Supports the development of firmonertinib as a first-line treatment for locally advanced or metastatic disease
Financial and Market Context
The clinical update arrives during a period of significant volatility for ArriVent, with the stock price declining 39.75% over the past month. This downward movement followed an October 6 announcement that the Phase 3 FURVENT trial missed its primary endpoint. Despite market pressure, ArriVent maintains a robust liquidity position, reporting $373.1 million in cash and investments as of June 30, 2026. Management expects these reserves to fund operations into 2028. Currently, the company is trading with an RSI of 25.8, while continuing to advance other pipeline assets, including its novel tetravalent antibody-drug conjugate ARR-002.
Down 30.6% since our story on 19 Oct: $16.66 when we broke it → $11.56 at the close on 16 Nov. Daily closing prices. Source: Yahoo Finance.
Show the prices
| 19 Oct | $17.94 |
|---|---|
| 20 Oct | $18.85 |
| 21 Oct | $19.12 |
| 22 Oct | $19.20 |
| 23 Oct | $21.00 |
| 26 Oct | $15.36 |
| 27 Oct | $15.40 |
| 28 Oct | $15.73 |
| 29 Oct | $15.95 |
| 30 Oct | $14.87 |
| 2 Nov | $13.35 |
| 3 Nov | $13.02 |
| 4 Nov | $13.49 |
| 5 Nov | $12.23 |
| 6 Nov | $13.64 |
| 9 Nov | $14.16 |
| 10 Nov | $13.49 |
| 11 Nov | $13.51 |
| 12 Nov | $13.07 |
| 13 Nov | $13.01 |
| 16 Nov | $11.56 |
Management Perspective
“We believe firmonertinib has the potential to change the treatment paradigm for EGFR PACC-mutant NSCLC, and these findings give us a strong foundation for our global Phase 3 ALPACCA trial.”
| Date | Announcement | Amount |
|---|---|---|
| 12 Oct 2026 | Dosing of first patient in Phase 1 clinical trial of novel tetravalent ADC ARR-002Source: ir.arrivent.com | – |
| 06 Oct 2026 | Phase 3 FURVENT trial of firmonertinib missed primary endpoint of progression-free survivalSource: ir.arrivent.com | – |
| 12 Aug 2026 | Second quarter 2026 financial results and pipeline progress reportedSource: ir.arrivent.com | – |
| 07 May 2026 | U.S. FDA IND clearance received for novel tetravalent ADC ARR-002Source: ir.arrivent.com | – |
| 22 Dec 2025 | First patient dosed in global pivotal Phase 3 ALPACCA trial of firmonertinibSource: ir.arrivent.com | – |
| 01 Jul 2025 | Pricing of underwritten public offering of common stock and pre-funded warrantsSource: lw.com | $75.0 Million |
Management commentary
“The publication demonstrated that firmonertinib’s unique molecular structure fits the EGFR PACC mutations very well, so this TKI has a unique potential high anti-tumor activity for this lung cancer patient population.”
“We continue to enroll patients in our global Phase 3 ALPACCA trial as we seek to address this area of high unmet medical need where there is no current standard of care.”
| Share price | $16.66 |
|---|---|
| Market cap | $821M |
| 1-month price change | -39.75% |
| Sector | HealthcareBiotechnology |
Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.
SEC filing by ArriVent BioPharma announcing the publication of Phase 1b clinical results for firmonertinib in Cancer Cell.
Track ArriVent BioPharma, Inc. live
Get the next ArriVent BioPharma, Inc. SEC filing seconds after it lands.
